Aurinia Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $11.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stacy Ku has given her Buy rating due to a combination of factors including the strong sales performance of Lupkynis, which exceeded expectations in the recent quarter. The management’s decision to raise the 2025 sales guidance for Lupkynis to $250-260 million, reflecting an 18% increase, indicates confidence in the product’s market potential despite a reduced sales force.
Furthermore, the positive feedback from key opinion leaders (KOLs) suggests that the usage of Lupkynis is expected to grow steadily as more experience is gained. The promising results from the Phase I study of aritinercept, along with upcoming proof-of-concept trials, also contribute to the optimistic outlook. Despite some disappointment over the company’s standalone status, the long-term potential of Lupkynis in the treatment of lupus nephritis supports the Buy rating, with expectations of significant market penetration in the future.
According to TipRanks, Ku is a 2-star analyst with an average return of 0.7% and a 54.74% success rate. Ku covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Aurinia Pharmaceuticals, and Supernus Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $17.00 price target.